辅助化疗延长完全切除的侵犯胸壁的T3N0非小细胞肺癌患者的生存期

Adjuvant chemotherapy prolongs survival in patients with non-small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non-small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non-small cell lung cancer with invasion of the chest wall.
辅助化疗延长N1或肿瘤>4cm的非小细胞肺癌患者的生存期。T3N0患者由于胸壁侵犯经常接受辅助化疗，是因为其疾病分类为Ⅱ期非小细胞肺癌。本研究评估化疗是否可改善胸壁侵犯T3N0非小细胞肺癌完全切除术后的生存期。

METHODS:方法：

Patients who underwent complete resection of N0 non-small cell lung cancer with invasion of the chest wall were identified in the National Cancer Database. We performed propensity matching of patients who received adjuvant chemotherapy and patients who did not and examined survival.
从国立癌症数据库确定接受完全切除术的胸壁侵犯的N0非小细胞肺癌。我们对接受与未接受辅助化疗的患者进行了倾向性匹配并研究其生存。

RESULTS:结果：

We identified 2326 eligible patients; 1050 patients (45%) received adjuvant chemotherapy, and 1276 patients (55%) did not. Patients who received chemotherapy after surgery had significantly better median survival than patients who did not (71 vs 39 months, P < .001). We identified 772 matched pairs. In the matched cohort, patients who received chemotherapy after surgery also had significantly better median survival (68 vs 39 months without chemotherapy, P < .001).
我们确定了2326例符合条件的患者；1050例（45%）患者接受了辅助化疗，1276例（55%）未接受辅助化疗。术后接受化疗的患者的中位生存期显著优于未接受化疗的患者（71个月对39个月，P＜0.001）。我们确定了772个配对。在配对队列中，术后接受化疗的患者中位生存期也明显优于对照组（68个月对无化疗的39个月，P＜0.001）。

CONCLUSIONS:结论：

In this large database study, adjuvant chemotherapy significantly improved survival in patients with T3 (chest wall) N0 non-small cell lung cancer after complete resection. Further studies are required to confirm our findings.
在本大型数据库研究中，辅助化疗显著延长T3（胸壁）N0非小细胞肺癌患者完全切除术后的生存期。需要进一步研究来证实我们的发现。